Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management (Q38076672)

28 August 2017

1 reference

title

Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management (English)

1 reference

chronic idiopathic myelofibrosis

28 August 2017

1 reference

1 reference

1

Ayalew Tefferi

1 reference

28 August 2017

publication date

1 February 2013

1 reference

American Journal of Hematology

28 August 2017

published in

1 reference

28 August 2017

volume

88

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

141-150

1 reference

Human factor IX in animals: kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions

28 August 2017

cites work

1 reference

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

LNK mutations in JAK2 mutation-negative erythrocytosis.

21 January 2018

1 reference

Pathogenesis of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

21 January 2018

1 reference

Conventional cytogenetics in myelofibrosis: literature review and discussion

21 January 2018

1 reference

Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.

21 January 2018

1 reference

Myelodysplasia with fibrosis: a distinct entity?

21 January 2018

1 reference

Acute panmyelosis with myelofibrosis: an entity distinct from acute megakaryoblastic leukemia

21 January 2018

1 reference

International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.

21 January 2018

1 reference

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

21 January 2018

1 reference

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival.

21 January 2018

1 reference

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

Modified kinetics of platelet-derived growth factor-induced Ca2+ increases in NIH-3T3 cells overexpressing phospholipase C gamma 1.

21 January 2018

1 reference

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

21 January 2018

1 reference

Evidence for the Platelet Specificity of β-Thromboglobulin and Studies on its Plasma Concentration in Healthy Individuals

21 January 2018

1 reference

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study

21 January 2018

1 reference

Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

Risk factors for leukemic transformation in patients with primary myelofibrosis

21 January 2018

1 reference

Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.

21 January 2018

1 reference

Outcome of transplantation for myelofibrosis

21 January 2018

1 reference

New and old treatment modalities in primary myelofibrosis

21 January 2018

1 reference

Thalidomide treatment in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Lenalidomide therapy in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis

21 January 2018

1 reference

Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level

21 January 2018

1 reference

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

21 January 2018

1 reference

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

21 January 2018

1 reference

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

Anti-platelet therapy and aspirin resistance - clinically and chemically relevant?

21 January 2018

1 reference

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

A patient with myelofibrosis complicated by refractory ascites and portal hypertension: to tips or not to tips? A case report with discussion of the mechanism of ascites formation

21 January 2018

1 reference

Transjugular intrahepatic portosystemic shunt for treatment of portal hypertension due to extramedullary hematopoiesis in idiopathic myelofibrosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/AJH.23384

1 reference

28 August 2017

1 reference